Editas Medicine, INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 5.8% of Editas Medicine, Inc. common stock as of June 30, 2026.

RA Capital Management, L.P. and affiliated entities have reported beneficial ownership of 5.8% of Editas Medicine, Inc. common stock.

TCG Crossover Fund III, L.P., along with its general partner and an individual, has reported beneficial ownership of 9.9% of Editas Medicine's common stock, including exercisable warrants.

Commodore Capital LP and its principals have reported a 9.9% beneficial ownership stake in Editas Medicine, Inc. following recent warrant acquisitions.

The Vanguard Group reported 0% beneficial ownership in Editas Medicine Inc. following an internal realignment, with subsidiaries now reporting separately.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.9% beneficial ownership stake in Editas Medicine, Inc. as of March 31, 2025.

Deep Track Capital, LP and its affiliates have reported a complete divestment of their beneficial ownership in Editas Medicine, Inc., holding 0% of the common stock as of December 31, 2024.